Technetium (99mTc) votumumab is a radioactive monoclonal antibody (mAb) used in imaging and treatment of certain types of cancer. It is a radiopharmaceutical, which is a medicinal preparation containing a radionuclide that is used to diagnose and treat various diseases. It works by binding to tumor cells and delivering a dose of radiation to kill them. The mAb binds to the tumor cell surface, where it is internalized and taken up by the cell. Once inside the cell, the radionuclide emits gamma rays that destroy the cell. Technetium (99mTc) votumumab can be used to detect and monitor the progression of certain types of cancer, such as breast cancer, non-small cell lung cancer, and colorectal cancer. It can also be used to treat certain types of cancer, such as non-Hodgkin’s lymphoma, leukemia, and multiple myeloma. The side effects of Technetium (99mTc) votumumab are generally mild and include nausea, vomiting, and fatigue.
Technetium (99mTc) votumumab, also known by the trade name Lucirem**, is a radiopharmaceutical agent under development for use in nuclear medicine imaging. It's important to note that Lucirem** is not yet commercially available and is still undergoing clinical trials. Here's what we know so far:
Components and Function:
- Technetium-99m (⁹⁹mTc): This is the radioactive component, a man-made isotope of technetium, which emits gamma rays used for imaging.
- Votumumab: This is a monoclonal antibody fragment that targets a specific protein called epithelial growth factor receptor 2 (EGFR2). EGFR2 is overexpressed on certain types of cancer cells.
Potential Medical Use:
The primary application of Technetium (99mTc) votumumab is envisioned for:
- Tumor Imaging: Lucirem**, if approved, could be used to image tumors that express EGFR2. This would help in:
- Detecting the spread of cancer (staging)
- Monitoring treatment response to therapies targeting EGFR2
Mechanism of Action (Expected):
- Injection and Targeting: Technetium (99mTc) votumumab is injected into a vein and travels through the bloodstream. Votumumab binds specifically to EGFR2 on the surface of cancer cells.
- Tumor Accumulation: If EGFR2-positive tumors are present, votumumab will bind to them, delivering the radioactive Tc-99m label.
- Gamma Ray Detection: The gamma rays emitted by decaying Tc-99m can be detected by a gamma camera. This allows for the visualization of tumors that have taken up votumumab, potentially highlighting areas of EGFR2 expression.